A prespecified pooled analysis of two large randomised pragmatic trials (DANFLU-2 and GALFLU) found high‑dose influenza vaccine reduced hospitalisation for influenza or pneumonia by 8.8% versus standard‑dose in adults ≥65 years, with larger effects for laboratory‑confirmed influenza.